How India Exports Tobramycin to the World

Tobramycin, an aminoglycoside antibiotic, has been approved in the United States through multiple Abbreviated New Drug Applications (ANDAs). The FDA's Orange Book lists several approved generic versions, indicating a well-established market presence. Notably, the FDA has not issued any import alerts specific to tobramycin, suggesting compliance with regulatory standards among exporters. The primary regulatory pathway for tobramycin involves the submission of an ANDA, demonstrating bioequivalence to the reference listed drug. Given that 62.3% of India's tobramycin exports are destined for the United States, the absence of import alerts underscores the adherence of Indian exporters to FDA requirements.

In the European Union, tobramycin has been authorized for various indications. For instance, Tobi Podhaler received marketing authorization on July 20, 2011, for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis patients aged six years and older. Similarly, Vantobra was authorized on February 18, 2019, for the same indication. These approvals necessitate compliance with the European Medicines Agency's (EMA) Good Manufacturing Practice (GMP) guidelines, ensuring product quality and safety. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring similar GMP compliance for tobramycin products.

Tobramycin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in treating priority health conditions. The 24th edition, published in September 2025, lists tobramycin as an essential medicine. This inclusion reflects its critical role in healthcare systems worldwide. Additionally, tobramycin formulations are standardized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, tobramycin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for tobramycin, allowing market-driven pricing. For export purposes, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products; however, tobramycin is not currently listed among those requiring an export NOC, facilitating its international trade.

The primary patents for tobramycin have expired, leading to a competitive generic market. This expiration has enabled multiple manufacturers to produce and export tobramycin, contributing to the substantial export figures from India. The presence of 283 active Indian exporters and a repeat buyer rate of 51.7% further illustrates the robust competition and sustained demand in the global market.

In May 2025, the WHO updated its Model List of Essential Medicines, reaffirming tobramycin's inclusion, which may influence procurement policies globally. In July 2025, the EMA approved a new generic version of tobramycin, enhancing market competition within the EU. In September 2025, the NPPA conducted a review of antibiotic pricing, though tobramycin's price remained unregulated, allowing market dynamics to dictate its cost. In November 2025, the FDA issued guidance on the manufacturing of aminoglycoside antibiotics, emphasizing compliance with current Good Manufacturing Practices (cGMP), which is pertinent to tobramycin producers. In January 2026, the CDSCO announced a streamlined process for the export of antibiotics, potentially benefiting tobramycin exporters by reducing bureaucratic hurdles.

India's pharmaceutical industry, renowned for its generic formulations, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of APIs used in Indian drug manufacturing are sourced from China, with certain critical KSMs being almost exclusively produced there. This dependency exposes the supply chain to significant risks, as disruptions in Chinese manufacturing—due to environmental regulations, geopolitical tensions, or other factors—can lead to shortages and increased costs for Indian pharmaceutical companies.

The COVID-19 pandemic underscored these vulnerabilities when Chinese factory shutdowns caused immediate API shortages, affecting global drug supplies. In response, the Indian government launched the Production Linked Incentive (PLI) scheme in October 2024, aiming to bolster domestic API and KSM production. This initiative led to the inauguration of two greenfield plants dedicated to manufacturing essential molecules like Penicillin G and 6-Aminopenicillanic acid (6-APA), marking a significant step toward reducing import dependence.

Our proprietary trade data indicates that the top five exporters of Tobramycin from India account for 64.0% of the total export value, with MANKIND PHARMA LIMITED alone contributing 20.7%. This high supplier concentration poses a risk, as disruptions affecting these key players could significantly impact global Tobramycin availability. While the PLI scheme has initiated efforts to diversify and strengthen domestic API production, the full impact on reducing supplier concentration remains to be seen.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt the transportation of pharmaceutical ingredients. Additionally, escalating US-China trade tensions have raised concerns about the stability of API and KSM supplies. The U.S. Pharmacopeia's Medicine Supply Map reveals that 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting the potential for significant supply chain disruptions.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different geographic regions to reduce reliance on a single country.

• Strengthen Domestic Production: Accelerate initiatives like the PLI scheme to enhance local manufacturing capabilities for critical APIs and KSMs.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the origin and movement of raw materials, enabling quicker responses to potential disruptions.

• Develop Strategic Reserves: Establish stockpiles of essential APIs and KSMs to buffer against short-term supply interruptions.

• Foster International Collaboration: Engage in partnerships and agreements with other nations to ensure a more resilient and diversified pharmaceutical supply chain.

RISK_LEVEL: HIGH